Press Releases

Press Releases

New Results Complement Earlier Positive Preclinical Data Demonstrating Increase in Brain Concentration Effects SOUTH SAN FRANCISCO, Calif., Sept. 3, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression,
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced that the Company will be presenting at the
Company Received Over $17.5 Million Net Proceeds from PH94B Upfront License Payment and Public Offering of Common Stock Subsequent to Quarter-end Positive Meeting with the FDA Sets Key Aspects of Pivotal PH94B Phase 3 Study SOUTH SAN FRANCISCO, Calif., Aug.
SAN FRANCISCO, Aug. 10, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the underwriters of its previously announced public
SOUTH SAN FRANCISCO, Calif., Aug. 5, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the closing of its previously announced
Collaboration intended to support Phase 3 development and commercialization of PH94B for anxiety-related disorders in key Asian markets SOUTH SAN FRANCISCO, Calif. and SHANGHAI, Aug. 4, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company
SOUTH SAN FRANCISCO, Calif., Aug. 2, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the pricing of its underwritten public
SOUTH SAN FRANCISCO, Calif., July 31, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced it has commenced an underwritten public
Company Reaches Consensus with FDA on Key Aspects of Novel Pivotal Phase 3 Study Agency Guidance May Provide Significant Time- and Cost-Efficiency for Phase 3 Program Approximately 17 Million American Adults Suffer from Social Anxiety Disorder SOUTH SAN FRANCISCO, Calif., July 23, 2020 /PRNewswire/
VistaGen Eligible to Receive up to $177 Million, Including Upfront and Potential Milestone Payments, in Addition to Royalties, under PH94B License in Key Asian Markets Announced Subsequent to Fiscal 2020 Year End SOUTH SAN FRANCISCO, Calif., June 29, 2020 /PRNewswire/ --  VistaGen Therapeutics
Displaying 51 - 60 of 197